Amgen
AMGN
has a diverse and growing portfolio of medicines in large therapeutic categories that it expects will help it drive growth through the end of the decade despite a declining pricing environment.
Amgen stock has risen 6% this year so far against a decrease of 12.6% for the
industry
.
Image Source: Zacks Investment Research
Amgen’s key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales driven by volume growth as these key drugs are gaining consistent approvals for label expansions. Moreover,
Amgen is also evaluating Prolia/Xgeva, Vectibix, Repatha, Nplate, Kyprolis and Blincyto for additional indications. Kyprolis is being investigated for weekly dosing in combinations with lenalidomide and dexamethasone for relapsed multiple myeloma while Repatha is being investigated for hypercholesterolemia as well as in a cardiovascular outcomes study (VESALIUS-CV) in patients with high cardiovascular risk without a prior heart attack or stroke in phase III. Nplate is being studied in phase III for chemotherapy-induced thrombocytopenia. Otezla was approved to treat plaque psoriasis in December 2021 while it is in phase III for moderate-to-severe genital psoriasis.
Amgen expects worldwide Otezla sales to grow by low double digits annually, on average, before its U.S. loss of exclusivity. Amgen acquired global commercial rights to Otezla from Celgene, which is now part of
Bristol-Myers
BMY
. The acquisition of Otezla from Bristol-Myers significantly strengthened its inflammation portfolio, which should boost long-term growth.
Repatha surpassed $1 billion of sales in 2021 and is expected to grow into a multi-billion-dollar franchise through 2030.
Amgen is also rapidly advancing its robust pipeline of early and late-stage assets. Several phase III readouts are due in 2022, which could act as catalysts for the stock.
A key drug, Lumakras (sotorasib), was approved for advanced non-small cell lung cancer (NSCLC) in the United States in May 2021 and EU in January 2022. It is now approved in 35 counties. Lumakras is off to an excellent start while its label expansion studies, which have the potential to significantly expand the currently addressable patient population, are progressing rapidly.
Amgen also boasts a strong biosimilars portfolio, which is an important long-term growth driver. Amgen markets Kanjinti (a biosimilar of
Roche
’s [
RHHBY
] Herceptin) and Mvasi ( a biosimilar of Roche’s Avastin) in the United States and Amgevita (a biosimilar of
AbbVie
’s [
ABBV
] Humira), Kanjinti and Mvasi outside the United States. In 2020, Amgen launched Avsola, a biosimilar of J&J/Merck’s blockbuster immunology medicine Remicade and in January 2021, the company launched Riabni, a biosimilar of Roche’s Rituxan. In the United States, AbbVie’s Humira biosimilar, Amjevita is expected to be launched in 2023.
In 2022, volume growth of biosimilars is expected to be offset by lower pricing due to increased competition and average sales price erosion. However, biosimilar revenues are expected to return to growth with the launch of Amjevita (AbbVie’s Humira biosimilar) in 2023.
Amgen faces its share of challenges. Pricing and competitive pressure are impacting many of Amgen’s products and franchises. Several of Amgen’s marketed drugs are facing increased pricing headwinds and continued COVID-19 headwinds. Nonetheless, continued strong growth of key drugs, higher sales from ex U.S. markets, increased contribution from its high-quality biosimilars and costs savings should keep the stock afloat in 2022.
Zacks Rank and Stock to Consider
Amgen currently has a Zacks Rank #3 (Hold). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
See these 7 breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
